

Richard Wang

CHINA PARTNER

Patents and
Innovations
Shanghai

rwang@wsgr.com



FOCUS AREAS

Intellectual Property
Life Sciences
Patents and Innovations

HIGHLIGHTS

- Extensive Cross-Border Collaboration Experience**
Richard has extensive experience in China-U.S. cross-border deals and helps clients with global visions. His unique view of China business and law from a global perspective helps his local clients in China embrace global opportunities/markets.
- Represents International and Local China Companies**
Richard represents both international and local China companies, including those that have been listed on Nasdaq or HKEX and those that are still being funded and growing quickly. As counsel for prestigious VC firms as well as for public offerings, Richard's experience helps his start-up clients prepare for financing or listing from an early stage. Further, his roots in local China business and Chinese culture are valuable assets for his international clients to explore business opportunities in China.
- Strategic Patent Counselor**
For over two decades, Richard has worked closely with innovators in the U.S., China, and beyond that are engaged in highly technical fields—including CRISPR, cell therapy, immunotherapeutics, medical devices, pharmaceuticals, and stem cells—to develop successful patents and IP strategies.

EXPERIENCE

Richard Wang is a China partner in the Shanghai office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. His practice includes patent preparation and prosecution, opinion work, freedom-to-operate and due-diligence studies, technology licensing, and litigation strategy.

Prior to joining the firm, Richard was a partner at NTD Patent and Trademark Agency Ltd., where his practice focused on consulting clients in the chemical, biological, and pharmaceutical industries, and representing clients before the Chinese Patent Office, Patent Re-examination Board, and courts. He was also previously an intern for Pfizer, Inc., in California, where he helped prosecute U.S. patent applications, supported R&D, and provided opinions to business units.

Richard is a native Mandarin speaker and is fluent in English.

CREDENTIALS

Education

- LL.M., The John Marshall Law School, Chicago
With Honors
- M.S., Pharmaceuticals, Shenyang Pharmaceutical University, Shenyang

Admissions

- Qualified in State Intellectual Property Office of the People's Republic of China
- State Bar of California

MATTERS

Select Representative Transactions

- Advised underwriters on Mirxes' IPO and SEHK Listing (2025)
- Advised Insilico on patent matters related to its global license agreement with Menarini Group (2025)
- Advised LaNova Medicines on its exclusive global license with Merck (2024)
- Advised Curon on patent matters related to its global license agreement with Merck (2024)
- Advised Insilico Medicine on its license agreement with Menarini Group (2024)
- Advised Insilico Medicine on its \$80 million license agreement with Exelixis (2023)
- Advised Boyu Capital on its Quasar Medical acquisition (2023)
- Advised LaNova Medicine on its \$600 million deal with AstraZeneca (2023)
- Advised underwriters on Luzhu Biotechnology's IPO (2023)
- Advised LaNova Medicines on its exclusive license agreement (2022)
- Advised LEPU ScienTech Medical on its US\$83.4 million Hong Kong IPO (2022)
- Advised InSilico Medicine on its collaboration with EQRx (2022)
- Advised underwriters on Sirnaomics' Hong Kong IPO (2021)
- Advised 6D and Ignis Therapeutics on Ignis' Series A, agreement with SKBP (2021)
- Advised Temasek on Abogen's \$700 million Series C financing (2021)
- Advised Lilly Asia Ventures on Regor Therapeutics' \$90 million Series B financing (2021)
- Advised Gracell on IP matters related to its IPO (2021)
- Advised LongRiver on Rona's \$35 million Series A+ financing (2024)
- Advised Orbimed Asia on Seeneuro Medical's Series B financing (2024)
- Advised Decheng on Yoltech's \$15 million Series A+ financing (2024)
- Advised Orbimed Asia on StairMed's financing (2023)
- Advised Temasek on Abogen's \$700 million Series C financing (2021)
- Advised Sequoia on CBMG's \$120 million Series A financing (2021)
- Advised Sequoia on StemiRNA's \$200 million Series B financing (2021)
- Advised Sequoia on Edigene's \$62 million Series B+ financing (2021)
- Advised IDG on MGI's \$1 billion Series B financing (2020)